Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Lizard King's Trading Swamp -- Ignore unavailable to you. Want to Upgrade?

To: TATRADER who wrote (4221)	1/29/1998 6:45:00 PM
From: Instock	Read Replies (1) \| Respond to of 7396

Mark, Others: I was surprised to see no mention about short selling CORR. Seems like a screaming Short sell. Three days of dropping, after todays crash open, should be a nice gain. IMO The fundies are not good, the News is a nice way of stating they blew it, the chart gives be something to look forward to. I know it was mentioned on this thread today that people need to start looking at LONG positions, and I agree with that. But there are still some very Nice Short Sells out there. IMO Some of the many stocks that have crashed in the past mmonths should become nice buys in the future, and a more affordable price. Thats weeks and months away for many, but something to watch!! Instock Jan 29, 1998 (6:26 PM ET) - The Motley Fool Evening News Pharmaceuticals development company COR Therapeutics (Nasdaq:CORR - news) plummeted $10 9/16 to $9 7/16 after the company's INTEGRILIN drug received recommendation for FDA approval for "use in the setting of coronary angioplasty." The FDA panel said, though, that it did not have enough data to recommend for approval the use of INTEGRILIN for treatment of acute coronary syndromes such as angina. CIBC Oppenheimer lowered its rating on the company to "hold" from "strong buy" and Lehman Brothers now rates the company at "outperform," down from "buy." One analyst told Reuters today that he estimates a yearly market potential of only $20 million for the drug, commenting "[INTEGRILIN is] going to be a marginal product because the FDA panel is recommending a sub-optimal dose and people won't want to use it."